No description available.

No description available.

The present research is focused on the topic of inflammation-drug interaction. Inflammation complicates many human diseases and conditions ranging from obesity to cancer. Therefore, the study of the effect of inflammation on drug pharmacokinetics and pharmacodynamics is pivotal. First, we tested the hypothesis that controlling inflammation using valsartan can restore the previously reported altered verapamil pharmacokinetics and pharmacodynamics. Such an effect is expected due to the anti-inflammatory properties of angiotensin II inhibition. Inflammation resulted in L-type calcium channel target protein (Cav1.2) downregulation and reduced verapamil potency in pre-adjuvant arthritis rat model. Valsartan treatment reversed the observed downregulation of L-type calcium channels thereby enhancing verapamil potency. This beneficial interaction, once proven in humans, may be of value in cardiac patients with superimposing inflammatory diseases. Second, we investigated whether the response to verapamil is reduced in experimentally induced acute myocardial injury (AMI) in rats. AMI caused a 75% reduction in verapamil potency and Cav1.2 target protein downregulation. If extrapolated to humans, our observations may suggest that L-type calcium channel downregulation can contribute, at least in part, to the poor outcome in myocardial infarction patients treated with calcium channel blockers (CCBs). Third, we studied the effect of obesity on the pharmacological response of CCBs in children with renal disease. Our data indicated that obese children are less responsive to CCBs than non-obese ones. Therefore, obesity should be considered when initiating antihypertensive drug therapy in children. Last, we were interested in finding out if the expression of other target genes is also altered by inflammation. We used real time polymerase chain reaction, after determination of the best housekeeping gene to be used as an internal control. Inflammation resulted in significant alterations of several molecular targets and transporters affecting the pharmacokinetics and pharmacodynamics of drugs. These findings may provide an insight into the effect of inflammation on drug targets and modulators of disease pathogenesis. In conclusion, inflammation is a missed ring in the chain of therapy. The research presented in this thesis will add to the inflammation-drug interaction field important findings that will help understanding the role of inflammation in pharmacotherapy outcomes. / pharmaceutical sciences

Thesis (Ph. D.)--University of Washington, 1996. / Vita. Includes bibliographical references (leaves [64]-71).

Orientador: André Sampaio Pupo / Banca: Wilma de Grava Kempinas / Banca: Edson Antunes / Resumo: A ejaculação precoce é a disfunção sexual masculina com maiores taxas de incidência e prevalência. De etiologia complexa, as principais abordagens farmacológicas desta condição têm sido a utilização de anestésicos locais, inibidores seletivos da recaptura de serotonina e mais recentemente, inibidores da fosfodiesterase tipo 5. O reflexo ejaculatório é um processo altamente organizado com a interação de áreas centrais encefálicas e espinhais, centros autonômicos simpáticos e parasimpáticos além de reflexos somáticos. O sistema nervoso autônomo simpático, através da ativação de adrenoceptores 1 ( 1-ARs), particularmente o subtipo 1A, desempenha papel fundamental na fase de emissão do reflexo ejaculatório através da modulação da contratilidade de órgãos como o ducto deferente, vesícula seminal e próstata. Além disso, a participação do influxo de cálcio extracelular via canais de cálcio dependentes de voltagem tipo L (canais de cálcio tipo L) na atividade contrátil destes órgãos é bem caracterizada. Devido à importância dos 1-ARs e canais tipo L no reflexo ejaculatório, este trabalho avaliou a eficácia do antagonista de 1-ARs Tamsulosin e das diidropiridinas bloqueadoras de canais de cálcio Nifedipina e (S)-(+)-Niguldipina no retardo da ejaculação em ratos. Os resultados obtidos demonstram que a atividade contrátil do ducto deferente e vesícula seminal ao estímulo adrenérgico via ativação de 1-ARs in vitro é fortemente inibida pelo antagonista de 1-ARs Tamsulosin e pelas bloqueadoras de canais de cálcio Nifedipina e (S)-(+)-Niguldipina. Entretanto, embora a contração destes órgãos e, portanto, a fase de emissão do reflexo ejaculatório tenha sido afetada, a latência ejaculatória dos animais não foi alterada. Estes resultados indicam que o bloqueio de canais de cálcio tipo L ou o antagonismo de 1-ARs no ducto deferente... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: Premature ejaculation is one of the most common male sexual dysfunctions. With complex aetiology, the main pharmacological approaches involve local anesthetics, selective serotonin reuptake inhibitors and, more recently, phosphodiesterase 5 inhibitors. The sympathetic nervous system plays a crucial role in the ejaculation, controlling vasa deferentia, seminal vesicles and prostate contraction through 1- adrenoceptor ( 1-AR) activation. In addition, the contractions of these organs are dependent on influx of extracellular calcium through L-type voltage-dependent calcium channels (L-type calcium channels). Due to the involvement of 1-ARs and L-type calcium channels in the ejaculatory reflex, this dissertation evaluated the efficacy of the 1-AR antagonist Tamsulosin and of dihydropyridine calcium channel blockers Nifedipine and (S)-(+)-Niguldipine in the delay of ejaculation in rats. The results showed that the vas deferens and seminal vesicle contraction in response to 1-AR activation is potently inhibited by Tamsulosin, Nifedipine and (S)-(+)- Niguldipine. However, although vas deferens and seminal vesicles contractions have been inhibited, the ejaculatory latency in vivo was not affected. These results show that although L-type calcium channel blockade and 1-ARs antagonism in the vas deferens and seminal vesicle are effective in the inhibition of events related to the seminal emission phase of ejaculation, they are not able to delay the ejaculation. The present results indicate that modulation of contractions of organs involved in seminal emission is not a suitable strategy to retard of ejaculation / Mestre

CoordenaÃÃo de AperfeiÃoamento de Pessoal de NÃvel Superior / A Alpinia zerumbet à uma planta da famÃlia Zingiberaceae, denominada popularmente âcolÃniaâ no Nordeste do Brasil. à utilizada com fins medicinais no tratamento de hipertensÃo e tem sido estudada em relaÃÃo as suas propriedades farmacolÃgicas. Esta pesquisa teve por objetivo analisar o efeito farmacolÃgico das fraÃÃes hexÃnica (FHOEAz), clorofÃrmica (FCOEAz) e metanÃlica (FMOEAz) do Ãleo essencial da Alpinia zerumbet (OEAz) na reatividade vascular in vitro e nos parÃmetros cardiovasculares in vivo. O projeto de pesquisa foi aprovado pela ComissÃo de Ãtica em Pesquisa Animal, da Universidade Federal do CearÃ, sob os protocolos n 55/10 e n 18/2011, de acordo com as normas de boas prÃticas que envolvem o uso de animais experimentais. Para todos os experimentos foram utilizados ratos Wistar machos. Realizaram-se experimentos de reatividade vascular no banho de ÃrgÃos, com preparaÃÃes de aorta isolada de rato, com endotÃlio Ãntegro e desnudo, mantidos em carbogÃnio e soluÃÃo de Krebs-Henseleit com concentraÃÃo em mmol/L: NaCl: 118,0; KCl: 4,7; KH2PO4: 1,2; MgSO4.7H2O; 1,2; NaHCO3: 15,0; CaCl2: 2,5 e Glicose: 5,5. Foi observada a variaÃÃo da tensÃo isomÃtrica e utilizados diferentes fÃrmacos inibidores especÃficos para anÃlise do mecanismo de aÃÃo do efeito vasodilatador. Analisou-se a pressÃo arterial indireta por pletismografia de cauda em ratos submetidos ao modelo de hipertensÃo por inibiÃÃo crÃnica do Ãxido nÃtrico, atravÃs da administraÃÃo do L-NAME, obtendo-se a pressÃo arterial sistÃlica, diastÃlica e mÃdia, frequÃncia cardÃaca, alÃm da variaÃÃo do peso corporal. Constatou-se que o OEAz, FHOEAz, FCOEAz e FMOEAz induzem relaxamento de anÃis aÃrticos prÃ-contraÃdos com Fenilefrina (1 mol/L), de forma dependente da dose, sendo a menor CE50 a da FMOEAz (150,45 g/mL). A administraÃÃo por gavagem de 100 mg/kg de OEAz, FHOEAz, FCOEAz e FMOEAz reduziu a pressÃo arterial em ratos hipertensos pelo modelo de inibiÃÃo crÃnica do Ãxido nÃtrico, um efeito que foi superior ao controle negativo com Ãgua destilada e inferior aos controles positivos com Captopril e Nifedipina. A FMOEAz (0,1 - 3000 g/mL) induz relaxamento dependente da dose em anÃis aÃrticos prÃ-contraÃdos com Fenilefrina (1 mol/L) ou KCl (80 mmol/L), com endotÃlio intacto ou desnudo. Os estudos de mobilizaÃÃo de cÃlcio mostraram que a FMOEAz inibe o influxo de Ca2+ do meio extracelular, bem como interfere na contraÃÃo induzida pela liberaÃÃo de Ca2+ dos estoques intracelulares pela Fenilefrina (1 mol/L) ou CafeÃna (30 mmol/L). A 4-aminopiridina (1 mmol/L) e a Iberiotoxina (30 nmol/L) aumentam a CE50 da FMOEAz, mas nÃo interferem no seu efeito vasodilatador final. A prÃ-incubaÃÃo com L-NAME (100 mol/L), ODQ (10 mol/L); Indometacina (10 mol/L), Atropina (1 mol/L), Catalase (500 U/ml), SOD (300 U/mL); Wortmannina (0,5 mol/L), TetraetilamÃnio (10 mmol/L), Apamina (1 mol/L); Caribdotoxina (15 nmol/L) e Glibenclamida (10 mol/L) nÃo interferiram no relaxamento induzido pela FMOEAz. Concluiu-se que o OEAz, FHOEAz, FCOEAz e FMOEAz possuem efeito hipotensor in vivo e vasodilatador in vitro, e que o mecanismo de aÃÃo da FMOEAz, provavelmente, envolve o antagonismo aos canais de cÃlcio dependentes de voltagem, aos canais de cÃlcio operados por receptor, interferindo tambÃm na liberaÃÃo de cÃlcio dos estoques intracelulares. / The Alpinia zerumbet is a plant of the family Zingiberaceae, popularly called "colÃnia" in Northeastern Brazil. It is used for medicinal purposes to treat hypertension and has been studied in relation to its pharmacological properties. This study aimed to analyze the pharmacological effect of hexanic (HFEOAz), chloroformic (CFEOAz), and methanolic (MFEOAz) fractions of the essential oil of Alpinia zerumbet (EOAz) in the vascular reactivity in vitro and cardiovascular parameters in vivo. The research project was approved by the Ethics Committee on Animal Research, of the Federal University of CearÃ, under protocol numbers 55/10 and 18/2011, according to the standards of good laboratory practice involving the use of experimental animals. For all experiments male Wistar rats were used. Experiments of vascular reactivity were conducted in organ bath, with preparations of isolated rat aorta with intact endothelium and desnuded, kept in carbogen and Krebs-Henseleit solution with a concentration in mmol/L: NaCl: 118,0; KCl: 4,7; KH2PO4: 1,2; MgSO4.7H2O; 1,2; NaHCO3: 15,0; CaCl2: 2,5 e Glicose: 5,5. Was observed variation in isometric tension and used different specific inhibitors to analyze the mechanism of action of the vasodilator effect. We analyzed blood pressure indirectly by tail plethysmography in rats submitted to chronic hypertension by inhibition of nitric oxide by the administration of L-NAME, obtaining the systolic, diastolic and mean blood pressure, heart rate, beyond variation in body weight. It was found that the EOAz, HFEOAz, CFEOAz MFEOAz induced relaxation of aortic rings pre-contracted with Phenylephrine (1 mol/L), of dose-dependent manner, with the smallest of the EC50 MFEOAz (150.45 mg/mL). The administration by gavage of 100 mg/kg EOAz, HFEOAz, CFEOAz MFEOAz reduced blood pressure in hypertensive rats by the model of chronic inhibition of nitric oxide, an effect that was greater than the negative control with distilled water and less than the positive controls with Captopril and Nifedipine. The MFEOAz (0.1 - 3000 Âg/mL) concentration dependently relaxed Phenylephrine (1 mol/L) and KCl (80 mmol/L) contracted rings with intact or denuded endothelium. Studies of calcium mobilization showed that FMOEAz inhibits the influx of Ca2+ from the extracellular environment and interferes with the contraction-induced Ca2+ release from intracellular stocks by Phenylephrine (1 mol/L) or Caffeine (30 mmol/L). The 4-aminopyridine (1 mmol/L) and Iberiotoxina (30 nmol/L) increased the EC50 of MFEOAz but do not interfere in its final vasodilator effect. The pre-incubation with L-NAME (100 mol/L), ODQ (10 mol/L), Indomethacin (10 mol/L), Atropine (1 mol/L), Catalase (500 U/mL), SOD (300 U/mL), Wortmannin (0.5 mol/L), Tetraethylammonium (10 mmol/L), Apamin (1 mol/L); Caribdotoxin (15 nmol/L) and Glibenclamide (10 mol/L) did not interfere with the relaxation induced by MFEOAz. It was concluded that the EOAz, HFEOAz, CFEOAz and MFEOAz have hypotensive effect in vivo and vasodilator effect in vitro, and that the mechanism of action of MFEOAz probably involves the antagonism of calcium channels voltage-dependent, the calcium channel operated by receptor, also interfering in the release of calcium from intracellular stores.

Thesis (doctoral)--Lund University, 1994. / Added t.p. with thesis statement inserted.

Made available in DSpace on 2014-06-11T19:25:25Z (GMT). No. of bitstreams: 0 Previous issue date: 2010-06-23Bitstream added on 2014-06-13T20:53:14Z : No. of bitstreams: 1 kiguti_lra_me_botib.pdf: 1147680 bytes, checksum: 2af4ebdd84a8cedf1deef8d15145e30a (MD5) / Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) / A ejaculação precoce é a disfunção sexual masculina com maiores taxas de incidência e prevalência. De etiologia complexa, as principais abordagens farmacológicas desta condição têm sido a utilização de anestésicos locais, inibidores seletivos da recaptura de serotonina e mais recentemente, inibidores da fosfodiesterase tipo 5. O reflexo ejaculatório é um processo altamente organizado com a interação de áreas centrais encefálicas e espinhais, centros autonômicos simpáticos e parasimpáticos além de reflexos somáticos. O sistema nervoso autônomo simpático, através da ativação de adrenoceptores 1 ( 1-ARs), particularmente o subtipo 1A, desempenha papel fundamental na fase de emissão do reflexo ejaculatório através da modulação da contratilidade de órgãos como o ducto deferente, vesícula seminal e próstata. Além disso, a participação do influxo de cálcio extracelular via canais de cálcio dependentes de voltagem tipo L (canais de cálcio tipo L) na atividade contrátil destes órgãos é bem caracterizada. Devido à importância dos 1-ARs e canais tipo L no reflexo ejaculatório, este trabalho avaliou a eficácia do antagonista de 1-ARs Tamsulosin e das diidropiridinas bloqueadoras de canais de cálcio Nifedipina e (S)-(+)-Niguldipina no retardo da ejaculação em ratos. Os resultados obtidos demonstram que a atividade contrátil do ducto deferente e vesícula seminal ao estímulo adrenérgico via ativação de 1-ARs in vitro é fortemente inibida pelo antagonista de 1-ARs Tamsulosin e pelas bloqueadoras de canais de cálcio Nifedipina e (S)-(+)-Niguldipina. Entretanto, embora a contração destes órgãos e, portanto, a fase de emissão do reflexo ejaculatório tenha sido afetada, a latência ejaculatória dos animais não foi alterada. Estes resultados indicam que o bloqueio de canais de cálcio tipo L ou o antagonismo de 1-ARs no ducto deferente... / Premature ejaculation is one of the most common male sexual dysfunctions. With complex aetiology, the main pharmacological approaches involve local anesthetics, selective serotonin reuptake inhibitors and, more recently, phosphodiesterase 5 inhibitors. The sympathetic nervous system plays a crucial role in the ejaculation, controlling vasa deferentia, seminal vesicles and prostate contraction through 1- adrenoceptor ( 1-AR) activation. In addition, the contractions of these organs are dependent on influx of extracellular calcium through L-type voltage-dependent calcium channels (L-type calcium channels). Due to the involvement of 1-ARs and L-type calcium channels in the ejaculatory reflex, this dissertation evaluated the efficacy of the 1-AR antagonist Tamsulosin and of dihydropyridine calcium channel blockers Nifedipine and (S)-(+)-Niguldipine in the delay of ejaculation in rats. The results showed that the vas deferens and seminal vesicle contraction in response to 1-AR activation is potently inhibited by Tamsulosin, Nifedipine and (S)-(+)- Niguldipine. However, although vas deferens and seminal vesicles contractions have been inhibited, the ejaculatory latency in vivo was not affected. These results show that although L-type calcium channel blockade and 1-ARs antagonism in the vas deferens and seminal vesicle are effective in the inhibition of events related to the seminal emission phase of ejaculation, they are not able to delay the ejaculation. The present results indicate that modulation of contractions of organs involved in seminal emission is not a suitable strategy to retard of ejaculation

This document only includes an excerpt of the corresponding thesis or dissertation. To request a digital scan of the full text, please contact the Ruth Lilly Medical Library's Interlibrary Loan Department (rlmlill@iu.edu).

Beta adrenergic antagonists and antianginal drugs are used with the aim to ultimately decrease mortality and enable patients to lead an improved quality of life by avoidance of anginal episodes. Each class of medications used for this purpose has a variety of actual or potential side effects associated with their use. Side effects and drug interactions involving these medications are discussed in the following chapter. Evidence presented should be used in the context of the patient populations described and may aid clinical decision making through avoidance or identification of actual or potential side effects. This review includes literature published from January 2019 to January 2020 written in English.